ArticleRheumatology and therapy2017
Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series.
Article in Rheumatology and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.Archives of dermatological research · 2023Trial
- Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study.Frontiers in medicine · 2022Article
- Tofacitinib-induced remission simultaneously in arthritis and vitiligo.European journal of rheumatology · 2021Article
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.Clinical, cosmetic and investigational dermatology · 2021Review
- Full histological and clinical regression of morphea with tofacitinib.Clinical rheumatology · 2020Article
- An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature.Clinical case reports · 2019Article
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.Dermatology and therapy · 2019Article
- Role of janus kinase inhibitors in the treatment of alopecia areata.Drug design, development and therapy · 2018Review
- Topical tofacitinib in treatment of alopecia areata.Einstein (Sao Paulo, Brazil)Article
- Which is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway.Indian dermatology online journalReview
- Effectiveness and Safety Profile of Oral Tofacitinib in Alopecia Areata: An Observational Study from a Tertiary Hospital.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlopecia universalis is an autoimmune disorder for which there is no known effective therapy. Tofacitinib-a novel antirheumatic therapy for rheumatoid arthritis-has been shown in some reports to induce sustained hair growth in patients with alopecia universalis. CASE SERIES: Here, we review the experiences of four different rheumatologists across the country regarding four Brazilian patients with alopecia universalis who were treated with tofacitinib . Two of these four patients had idiopathic alopecia and the other two had rheumatoid arthritis; in each case, the alopecia universalis was apparently induced by etanercept.
conclusionTofacitinib should be considered for the treatment of severe alopecia areata, but the optimal dose and duration of therapy should be defined in randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.